S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Stock ideas from the 2024 Microcap Conference
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
AI Stock Caught Trading Under Secret Name (Ad)
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
MarketBeat Week in Review – 2/19 - 2/23
AI Stock Caught Trading Under Secret Name (Ad)
Closing prices for crude oil, gold and other commodities
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Stock ideas from the 2024 Microcap Conference
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
AI Stock Caught Trading Under Secret Name (Ad)
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
MarketBeat Week in Review – 2/19 - 2/23
AI Stock Caught Trading Under Secret Name (Ad)
Closing prices for crude oil, gold and other commodities
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Stock ideas from the 2024 Microcap Conference
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
AI Stock Caught Trading Under Secret Name (Ad)
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
MarketBeat Week in Review – 2/19 - 2/23
AI Stock Caught Trading Under Secret Name (Ad)
Closing prices for crude oil, gold and other commodities
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Stock ideas from the 2024 Microcap Conference
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
AI Stock Caught Trading Under Secret Name (Ad)
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
MarketBeat Week in Review – 2/19 - 2/23
AI Stock Caught Trading Under Secret Name (Ad)
Closing prices for crude oil, gold and other commodities
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
NASDAQ:IMMU

Immunomedics (IMMU) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$87.86
$87.86
50-Day Range
$85.08
$87.86
52-Week Range
$8.80
$87.93
Volume
N/A
Average Volume
4.01 million shs
Market Capitalization
$20.31 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

IMMU stock logo

About Immunomedics Stock (NASDAQ:IMMU)

Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. It develops sacituzumab govitecan, an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140 for treatment of hematologic malignancies; and IMMU-130 to treat Colorectal cancer. Its other product candidates includes epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with GBG Forschungs GmbH to develop sacituzumab govitecan for the treatment of breast cancer; and clinical collaboration with F. Hoffman-La Roche Ltd to treat patients with metastatic or inoperable locally advanced TNBC versus atezolizumab plus nab-paclitaxel as standard of care. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey. As of October 23, 2020, Immunomedics, Inc. operates as a subsidiary of Gilead Sciences, Inc.


IMMU Stock News Headlines

New Bitcoin Projection: $165,000 in the Next 18 Months
New Bitcoin ETFs... Trillions in Cash Pouring in… Crypto is Set to Experience Another Major Bull Run.The Event is Scheduled for April 22. See Why This Will Send Crypto Soaring Again Here.
Gilead to buy CymaBay in $4.3B deal for liver disease drug
Arvinas Appoints Jared Freedberg as General Counsel
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE
A shocking leak has revealed tech giant Microsoft plans to add crypto support to future products. If the plans in these leaked documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, and MORE. The coupling of gaming and cryptocurrency could transform digital finance as we know it. We've gathered 27 experts to share their top picks and predictions for the 2024 crypto bull run.
Spate of Deal News Juices Start of This Week's Trading
Antibody Drug Conjugate (ADC) Markets, 2035
8 Undervalued Quality Healthcare Stocks
See More Headlines
Receive IMMU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunomedics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/05/2020
Today
2/24/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic Substances
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:IMMU
CUSIP
45290710
Fax
N/A
Employees
366
Year Founded
N/A

Profitability

Net Income
$-357,190,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$290,000.00
Price / Sales
70,028.66
Book Value
$1.38 per share

Miscellaneous

Free Float
N/A
Market Cap
$20.31 billion
Optionable
Optionable
Beta
2.90
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Behzad Aghazadeh Ph.D. (Age 49)
    Exec. Chairman
    Comp: $147.53k
  • Mr. Usama Malik (Age 45)
    CFO & Chief Bus. Officer
    Comp: $533.39k
  • Mr. Brendan P. Delaney (Age 45)
    Chief Commercial Officer
    Comp: $527.63k
  • Mr. Bryan Ball (Age 50)
    Chief Quality Officer
    Comp: $646.48k
  • Mr. William Fricker (Age 55)
    Principal Accounting Officer, Exec. Director & Corp. Controller
  • Ms. Phyllis Parker
    Director of Admin.
  • Dr. Chau Cheng
    Sr. Director of Investor Relations
  • Mr. Jared Freedberg (Age 52)
    Gen. Counsel & Corp. Sec.
  • Mr. Kurt J. W. Andrews (Age 51)
    Chief HR Officer
  • Dr. Loretta M. Itri (Age 70)
    Chief Medical Officer

Should I Buy Immunomedics Stock? IMMU Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Immunomedics was last updated on Tuesday, February 20, 2024 at 2:39 PM.














IMMU Stock Analysis - Frequently Asked Questions

How were Immunomedics' earnings last quarter?

Immunomedics, Inc. (NASDAQ:IMMU) announced its quarterly earnings results on Wednesday, August, 5th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by $0.39. The biopharmaceutical company earned $20.07 million during the quarter, compared to analysts' expectations of $24.81 million.

What other stocks do shareholders of Immunomedics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunomedics investors own include Micron Technology (MU), NVIDIA (NVDA), Seagen (SGEN), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Gilead Sciences (GILD), Exelixis (EXEL), ImmunoGen (IMGN) and Intel (INTC).

This page (NASDAQ:IMMU) was last updated on 2/24/2024 by MarketBeat.com Staff